1型糖尿病单独胰岛移植的长期结局:意大利20年单中心研究
该研究回顾性分析了意大利米兰IRCCS Ospedale San Raffaele的79例1型糖尿病单独胰岛移植患者,随访中位13.1年。移植后糖化血红蛋白和胰岛素需求量显著下降,中位移植物存活3.9年,44%患者实现胰岛素不依赖(中位6年);接受>10000 IEQ/kg联合BAS、FK506和Rapa方案者移植物存活更优。免疫抑制治疗相关不良事件发生率为44%。
要点
- 79例患者接受159次胰岛输注,中位总胰岛当量9637 IEQ/kg,严重并发症需手术干预者仅3%。
- 移植后HbA1c降低10.04 mmol/mol,每日胰岛素需求减少13.35单位,中位移植物存活3.9年。
- 接受>10000 IEQ/kg联合BAS、FK506和Rapa方案者中位移植物存活9.7年,73%实现胰岛素不依赖。
核心结论
- 该大型单独胰岛移植队列分析提供了影响结局因素的有价值见解并突出了潜在风险,支持知情临床决策和未来β细胞替代策略的优化。
研究设计与样本
- 回顾性队列研究,纳入2001年2月16日至2023年6月1日在意大利米兰IRCCS Ospedale San Raffaele接受经门静脉单独胰岛移植的18-67岁1型糖尿病患者,共79例,接受159次胰岛输注。
- 纳入标准为55岁前诊断的1型糖尿病成人,伴有严重反复低血糖或血糖不稳定;主要排除标准包括HbA1c>12.5%、BMI>30 kg/m2、胰岛素需求>1.2 IU/kg/天以及免疫抑制治疗禁忌证。
- 采用意向性治疗分析、混合效应模型、Kaplan-Meier估计以及Cox和逻辑回归分析。
主要发现
- 移植后HbA1c降低10.04 mmol/mol(95%CI -13.63至-6.46),每日胰岛素需求量减少13.35单位(95%CI -17.04至-9.65)。
- 意向性治疗分析显示中位移植物存活(空腹C肽≥0.3 ng/mL)为3.9年(95%CI 1.6至6.2),44%(35/79)患者实现胰岛素不依赖,中位持续6年(95%CI 2.88至9.08)。
- 接受>10000 IEQ/kg联合BAS、FK506和Rapa治疗的患者中位移植物存活9.7年(3.1-16.0),73%(16/22)实现胰岛素不依赖。
- Kaplan-Meier估计移植物存活率1年86%、5年65%、10年47%、15年47%、20年40%;中位随访13.1年期间总生存率92%(73/79),20年生存概率84%。
- 免疫抑制治疗相关不良事件发生率为44%(35/79),同种致敏率从基线6%增至治疗停止后42%。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Islet transplantation has the potential to cure type 1 diabetes by restoring endogenous insulin production. However, its success relies on balancing improved glycaemic control with the risks of immunosuppressive therapy. This study aimed to evaluate long-term outcomes of islet transplantation alone for type 1 diabetes, focusing on the effects of islet mass and immunosuppressive regimens on graft survival and insulin independence, and weighing glycaemic control benefits against the risks of immunosuppressive therapy. METHODS: This cohort study retrospectively analysed individuals aged 18-67 years with type 1 diabetes who received intraportal islet transplantation alone at IRCCS Ospedale San Raffaele, Milan, Italy. Inclusion criteria comprised adults with type 1 diabetes diagnosed before the age of 55 years with severe recurrent hypoglycaemia or glycaemic instability. Major exclusion criteria included a HbA1c of more than 12·5%, a BMI of more than 30 kg/m2, and insulin requirements exceeding 1·2 IU/kg per day, along with contraindications to immunosuppressive therapy. Participants were recruited from the hospital's islet transplant registry. Follow-up was conducted through regular clinical visits, with data collected retrospectively. Outcomes assessed included patient survival, graft survival, insulin independence, glycaemic control, and adverse events. Data were analysed using an intention-to-treat method, mixed-effects models, Kaplan-Meier estimates, and Cox and logistic regression to identify factors linked to metabolic success and reduced risks. FINDINGS: 79 patients underwent intrahepatic or intraportal islet transplantation alone between Feb 16, 2001, and June 1, 2023, and received a total of 159 islet infusions, with a median total islet mass of 9637 islet equivalents (IEQ) per kg. Complications were infrequent and mostly involved minor bleeding, with only 3% (two of 79) of patients requiring surgical intervention. Glycaemic control improved significantly after infusion, with a reduction of HbA1c by -10·04 mmol/mol (-13·63 to -6·46), and a decrease in daily insulin requirements by -13·35 units per day (-17·04 to -9·65). The intention-to-treat analysis showed a median graft survival (fasting C peptide ≥0·3 ng/mL) of 3·9 years (95% CI 1·6 to 6·2) and 44% (35/79) insulin independence for a median of 6 years (95% CI 2·88 to 9·08). Patients receiving more than 10 000 IEQ/kg with BAS, FK506, and Rapa therapy had a median graft survival of 9·7 years (3·1-16·0) and 73% (16 of 22) insulin independence. Kaplan-Meier estimates indicated graft survival rates of 86% at 1 year, 65% at 5 years, 47% at 10 years, 47% at 15 years, and 40% at 20 years. Overall survival was 92% (73 of 79) over a median follow-up of 13·1 years, with a 20-year survival probability of 84%. Adverse events related to immunosuppressive therapy were reported in 44% (35 of 79) of patients, with allosensitisation rates increasing from 6% at baseline to 42% after therapy discontinuation. INTERPRETATION: This analysis of a large islet transplantation alone cohort provides valuable insights into factors influencing outcomes and highlights potential risks, supporting informed clinical decision making and the optimisation of future β-cell replacement strategies. FUNDING: None.
引用
- Catarinella D, Melzi R, Mercalli A, et al. Long-term outcomes of pancreatic islet transplantation alone in type 1 diabetes: a 20-year single-centre study in Italy. Lancet Diabetes Endocrinol. 2025. PMID: 39929222. doi:10.1016/S2213-8587(24)00341-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。